Greg received his A.B. degree in biochemistry from Middlebury College and M.D. from New York Medical College. He completed a residency training in Internal Medicine at Dartmouth-Hitchcock Medical Center and a fellowship training in Hematology and Oncology at The University of Chicago Hospitals, where he joined as a junior faculty member in the Department of Medicine. Greg joined Amgen in 2006 and has served in a variety of roles over the past 13 years. In 2011 he became group leader and Therapeutic Area Head, Oncology Early Development focused on phase 1 drug development. In 2015 he took on the role of Global Product General Manager overseeing the multi-disciplinary development of blinatumomab and the bispecific t-cell engager portfolio. In 2017 Greg assumed the role of Vice President and TA Head, Hematology/Oncology Global Development, overseeing a group of about 40 physicians dedicated to developing new cancer and bone health drugs.

Biochemistry Health & Wellness, Healthcare, Oncology, Medicine, Pharmaceutical / Medical, Cancer, Science, Business & Economics,